0
%
of contact lens wearers drop out due to comfort issues
0
%
of dry eye is caused by Meibomian Gland Dysfunction (MGD)
0
%
of contact lens intolerant patients had Meibomian Gland Dysfunction (MGD)

How can ECPs integrate VibrantVue® into their practice?

PREVENT

Prescribe VibrantVue® as a preventative treatment for Contact Lens Intolerance. This can apply to both new and returning patients to avoid irritation and keep eyes healthy.

TREAT

The two-product regimen is an ideal base treatment plan for their Dry Eye patients that can be utilized alone or in conjunction with other treatments (heating devices, lid expression, IPL, etc.).

MAINTAIN

MGD management is vital to long-term contact lens success. Contact Lens Intolerance & MGD are both responsive to VibrantVue®’s antibacterial & anti-inflammatory effects.

The VibrantVue® Difference

Bacteria (& Blepharitis)

  • The active ingredient in VibrantVue® is a remarkable, broad-spectrum antimicrobial agent that is used by your body’s own white blood cells to fight infection
  • Kills bacteria on the lids and can be used as a lid scrub to remove debris

Inflammation

  • The anti-inflammatory effects of the active agent in VibrantVue® have been shown to work through 5 different inflammatory pathways

Oils

  • VibrantVue® helps to open up clogged Meibomian glands
  • That combined with the antibacterial & anti-inflammatory effects can dramatically improve the symptoms of dry eye disease

What about Contact Lens Intolerance?

An estimated 50 Million people wear contact lenses in the U.S.

Recent studies demonstrated a 25% dropout rate for new contact lens wearers. This translates into a large loss of revenue for the ECPs.

Is there a relationship between Contact Lens Intolerance and MGD? YES.

  • One study showed that almost 40% of contact lens intolerant patients had MGD
  • Another study showed a 50% increase in MGD in CL wearers after 6 months of wear compared to Non-CL wearers

The number of functional MGs decreases with age.

One study showed that the average age of CL wearers was 31 years in the study, but the Meibomian glands (MGs) were similar to the 60-69-year-old group in the non-CL wearers group. The Meibomian gland decrease in the CL wearers worsened with the duration on CL wear but was not related to whether the patients wore RGP or soft lenses.

Next Generation Hypochlorous Technology for Eye Health